The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results or events to materially differ. Accordingly, investors should monitor PardesвЂ™ Investors website, in addition to following PardesвЂ™ press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcasts. Pardes intends to use the Investors page of its website ( ) as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD (Fair Disclosure). For more information, please visit Availability of Other Information about Pardes Biosciences PBI-0451 is currently in a Phase 1 placebo-controlled, blinded, randomized, dose escalation study in healthy volunteers in New Zealand evaluating the safety, tolerability, and pharmacokinetics of PBI-0451 after single and multiple ascending doses. PBI-0451 is being developed for the treatment and prevention of SARS-CoV-2 infection and associated diseases. This protease is highly similar across all coronaviruses, including known and emerging coronavirus variants. PBI-0451 is an investigational orally bioavailable direct-acting antiviral (DAA) inhibitor of the main protease (Mpro), an essential protein required for the replication of coronaviruses, including the novel SARS-CoV-2 that causes COVID-19. For more information, please visit About PBI-0451 We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates, including our lead product candidate PBI-0451, while reimagining the patient journey to access these medicines. Pardes Biosciences is a clinical-stage biopharmaceuticalвЂ‰company created to help solve pandemic-sized problems, starting with COVID-19. Pardes anticipates reporting data from this ongoing study at a scientific conference later this quarter.

PB-0451 is currently under evaluation in a Phase 1 placebo-controlled, blinded, randomized, dose escalation study in healthy volunteers in New Zealand evaluating the safety, tolerability, and pharmacokinetics of PBI-0451 after single and multiple ascending doses. Pending additional engagement with FDA and other regulators, we anticipate initiating our global Phase 2/3 studies of PBI-0451 in SARS-CoV-2 infected patients in mid-2022.вЂќ

вЂњThe clearance of our IND for PBI-0451 enables us to proceed with the initiation of additional Phase 1 clinical trials for PBI-0451 in the U.S. вЂњAs we enter our third year of a global pandemic, we believe the value of oral direct-acting antivirals for SARS-CoV-2 has become increasingly clear, especially if they can be given as standalone therapies,вЂќ said Uri A. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), today announced that its Investigational New Drug (IND) application for PBI-0451 has been cleared by the United States Food and Drug Administration (FDA). 03, 2022 (GLOBE NEWSWIRE) - Pardes Biosciences, Inc.

Pardes biosciences